SUPERCENTENARIAN INDUCED PLURIPOTENT STEM (sciPS) CELLS AND METHODS OF MAKING AND USING THEREOF

Abstract

Provided herein are cells and methods for reprogramming iPS cells from a supercentanarian and their differentiated derivatives having differences from non-supercentenarian iPS derived cells that contribute to disease resistance and longevity. Additionally, provided herein are methods for treatment and prevention of age related diseases by administration of therapeutic sciPS derived cells or cell derived reagents. Also provided herein, are methods for identifying reagents for treatment of age related diseases using sciPS cell-based assays.

1 - 20 . (canceled) 
     
     
         21 . A method of generating reprogrammed supercentenarian stem cells capable of differentiating into stem cells with a slower rate of accumulation of cellular aging changes; the method comprising:
 a. collecting a cell sample from a validated supercentenarian individual;   b. reprogramming cells from the cell sample into supercentenarian induced pluripotent (iPS) cells; and   c. identifying reprogrammed supercentenarian induced pluripotent stem (sciPS) cells which are capable of differentiating into cells which exhibit decelerated replicative aging as compared to stem cells from iPS cells from a non-supercentenarian donor.   
     
     
         22 . The method of  claim 21 , further comprising:
 d. deriving stems cells from the sciPS which exhibit decelerated replicative aging as compared to stem cells from iPS cells from a non-supercentenarian donor, thereby generating stem cells having a slower rate of accumulation of cellular aging changes as compared to stem cells from iPS cells from a non-supercentenarian donor.   
     
     
         23 . The method of  claim 21 , wherein the cellular aging changes are selected from the group consisting of shortened telomeres, loss of differentiation capacity, changes in differentiation propensity, changes in genomic methylation, changes in genome expression pattern, morphological changes, and expression of senescence associated markers and gene expression. 
     
     
         24 . The method of  claim 21 , wherein the sciPS cells exhibit telomere length resetting towards embryonic length. 
     
     
         25 . The method of  claim 21 , wherein the supercentenarian individual is a human. 
     
     
         26 . The method of  claim 21 , wherein the stem cells are mesenchymal stromal cells (MSC) or hematopoietic stem cells (HSC). 
     
     
         27 . The method of  claim 21 , wherein cells from the cell sample are selected from the group consisting of blood cells, dermal fibroblasts, adipose cells and hair follicle cells. 
     
     
         28 . An isolated population of stem cells differentiated from supercentenarian iPS cells (sciPS), wherein the stem cells exhibit a slower rate of accumulation of cellular aging changes as compared to stem cells from iPS cells from a non-supercentenarian. 
     
     
         29 . The isolated stem cells of  claim 28 , wherein the cellular aging changes are selected from the group consisting of shortened telomeres, loss of differentiation capacity, changes in differentiation propensity, changes in genomic methylation, changes in genome expression pattern, morphological changes, and expression of senescence associated markers and gene expression. 
     
     
         30 . The isolated stem cells of  claim 28 , wherein the iPS cells exhibit telomere length resetting towards embryonic length. 
     
     
         31 . The isolated stem cells of  claim 28 , which are human stem cells.